Dr. Jennifer Edith De Niro, MD

Dr. De Niro practices at Brown & Toland Medical Group in Oakland, California.

Dr. De Niro's NPI, 1669782124, was assigned on October 19, 2010. Dr. De Niro graduated from UCSF School of Medicine in 2009. Dr. De Niro holds California license A115886.

Dr. De Niro's primary practice is Brown & Toland Medical Group, at 491 30th St, Oakland, CA 94609. The practice phone is (510) 836-2122.

Dr. De Niro's primary practice is Brown & Toland Medical Group in Oakland, California. Dr. De Niro is also affiliated with Alameda Health System - Highland Hospital. The medical group on file is Alameda Health System. Dmand AI also links Dr. De Niro to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De Niro practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. De Niro's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. De Niro is board certified in ophthalmology by the American Board of Ophthalmology. Dr. De Niro is licensed in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. De Niro treats.

CMS data shows 2,273 Medicare services from Dr. De Niro across 18 procedure codes in 2024, for 947 Medicare patients. Medicare paid $250,813 for them.

CMS counts 947 Medicare patients who saw Dr. De Niro in 2024. The largest group is 65 to 74, with 380 patients. 74% of them have high cholesterol, and 67% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. De Niro's median patient age at 73, with 50% women.

In 2024, Dr. De Niro wrote 2,386 Medicare Part D claims for 475 patients. 55% of them were for generic drugs. CMS names the drug for 2,226 of them, across 25 drugs with 11 or more claims each, at $322,542 in total drug cost. In 2023, CMS named 2,213 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. De Niro for performance year 2024, reported individually. Dr. De Niro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 184 procedures of cataract surgery by Dr. De Niro, more than 83% of the clinicians it reports for that procedure.

Dmand AI links 8 papers to Dr. De Niro, published from 2011 to 2014. Dr. De Niro has published most often in Retin Cases Brief Rep. Dr. De Niro's most frequent co-authors are Emmett T. Cunningham, MD, MPH, PhD, Robert N. Johnson, MD and J Michael Jumper, MD.

CMS Open Payments shows 251 general payments to Dr. De Niro from 27 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $1,301.

Dr. De Niro graduated from UCSF School of Medicine in 2009.

Dr. De Niro is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.